CeleCor Therapeutics Reports Positive Results of Phase 3 Trial for Heart Attack Drug Disaggpro CeleCor Therapeutics has announced positive primary results from its Phase 3 trial for Disaggpro™, a new anti-platelet drug aimed at heart attack treatment.

CeleCor Therapeutics Reports Positive Results of Phase 3 Trial for Heart Attack Drug Disaggpro #United_States #Del_Mar #CeleCor #Disaggpro #heart-attack

CeleCor Therapeutics Advances Heart Attack Treatment with Disaggpro in Phase 3 Study Completion CeleCor Therapeutics has finished its multinational Phase 3 trial of Disaggpro, an innovative drug aimed at treating heart attacks swiftly at the initial medical contact.

CeleCor Therapeutics Advances Heart Attack Treatment with Disaggpro in Phase 3 Study Completion #United_States #Del_Mar #CeleCor #Disaggpro #STEMI